Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists

J Med Chem. 2013 Feb 28;56(4):1693-703. doi: 10.1021/jm301774u. Epub 2013 Feb 18.


The M5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M5 over M1 receptor and shows little activity at M2-M4. This compound, although exhibiting modest affinity (K(i) = 2.24 μM) for the [(3)H]N-methylscopolamine binding site on the M5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [(3)H]DA release from rat striatal slices. Further, a homology model of human M5 receptor based on the crystal structure of the rat M3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • CHO Cells
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Cricetinae
  • Cricetulus
  • Dopamine / metabolism
  • Esters
  • Humans
  • In Vitro Techniques
  • Molecular Docking Simulation
  • Muscarinic Agonists / pharmacology
  • Oxotremorine / pharmacology
  • Pyridines / chemical synthesis*
  • Pyridines / chemistry
  • Pyridines / pharmacology
  • Radioligand Assay
  • Rats
  • Receptor, Muscarinic M5 / antagonists & inhibitors*
  • Structure-Activity Relationship


  • Esters
  • Muscarinic Agonists
  • Pyridines
  • Receptor, Muscarinic M5
  • Oxotremorine
  • Dopamine